BioSpace News Archive

Centinel Spine®, LLC announced record full-year 2022 performance and a top position in the TDR market.

Kurin, Inc., the inventor and manufacturer of the Kurin® blood culture collection sets, announced today that the Food and Drug Administration has issued a 510(k) clearance for the Kurin product line. Kurin now has four 510(k) clearances from the FDA.

Elixir Medical, a developer of breakthrough cardiovascular technologies, announced that data from its BIOADAPTOR RCT randomized controlled trial, an international, multicenter, single-blind study enrolling 445 patients will be presented at the EuroPCR conference in Paris.

Gyros Protein Technologies AB, a leading provider of peptide synthesizers and reagents and a pioneer in automated nanoliter-scale immunoassays, today announced the introduction of Gyrolab® Generic Cyno Anti-Drug Antibodies (ADA) Kit Reagents, for the detection of circulating immune complexes of human IgG with cyno anti-human IgG.

The Insight Partners published latest research report on “Biosafety Cabinet Market Size Report, Share, Growth, Trends & Forecasts to 2028 - COVID-19 Impact and Global Analysis By Products Handled, Category, Type, Application and End User”,

Viscient Bio, Inc. (“Viscient”) today announced it has identified the world’s first drug candidate discovered primarily using 3D bioprinted tissue models of disease formed from human cells.

Interactive Strength Inc. (FORME) (Nasdaq: TRNR), a digital fitness platform that combines premium connected fitness hardware products with personal training and coaching, today announced the closing of its initial public offering of an aggregate of 1,500,000 shares of its common stock at a price to the public of $8.00 per share.

Bioxodes SA, a company specializing in the development of novel therapies for the prevention and treatment of thrombotic and inflammatory diseases, today announces it has been selected to present at key international business and scientific conferences this spring and early summer:

A new study from the Family Heart Foundation, a leading research and advocacy organization, showed the diagnosis and treatment of homozygous familial hypercholesterolemia (HoFH) is delayed, and often occurs after a heart attack or early atherosclerotic cardiovascular disease (ASCVD).

Aurinia Pharmaceuticals Inc. announced that the Swiss Agency for Therapeutic Products has granted marketing authorization of LUPKYNIS® in combination with a background immunosuppressive therapy to treat adults with active class III, IV and V lupus nephritis, a serious complication of systemic lupus erythematosus.